4461

DKS Co.Ltd.

第一工業製薬

Industry
Chemicals
Market
Prime
Accounting standards
Japanese GAAP
Consolidation basis
Consolidated

Key metrics

Revenue(million JPY)

Mar 2022
62,672
Mar 2023
65,081
Mar 2024
63,118
Mar 2025
73,255
Mar 2026
82,886

Operating profit(million JPY)

Mar 2022
4,626
Mar 2023
1,186
Mar 2024
2,077
Mar 2025
5,351
Mar 2026
10,107

Operating profit margin(%)

Mar 2022
7.38
Mar 2023
1.82
Mar 2024
3.29
Mar 2025
7.3
Mar 2026
12.19

Profit before tax(million JPY)

Mar 2022
4,179
Mar 2023
224
Mar 2024
2,343
Mar 2025
5,194
Mar 2026
9,892

Profit(million JPY)

Mar 2022
2,492
Mar 2023
-407
Mar 2024
1,174
Mar 2025
2,585
Mar 2026
6,169

Total assets(million JPY)

Mar 2022
86,469
Mar 2023
85,025
Mar 2024
94,537
Mar 2025
97,113
Mar 2026
115,003

Cash and cash equivalents(million JPY)

Mar 2022
12,151
Mar 2023
9,051
Mar 2024
15,947
Mar 2025
16,556
Mar 2026
23,830

Cash flows from operating activities(million JPY)

Mar 2022
5,520
Mar 2023
724
Mar 2024
7,091
Mar 2025
7,528
Mar 2026
9,962

Cash flows from investing activities(million JPY)

Mar 2022
-2,700
Mar 2023
-2,883
Mar 2024
-2,008
Mar 2025
-2,138
Mar 2026
-3,536

Cash flows from financing activities(million JPY)

Mar 2022
-2,336
Mar 2023
-1,030
Mar 2024
1,646
Mar 2025
-5,045
Mar 2026
854

Return on equity(%)

Mar 2022
7
Mar 2023
-1.1
Mar 2024
3.3
Mar 2025
6.9
Mar 2026
13.6

Equity ratio(%)

Mar 2022
42.5
Mar 2023
40.4
Mar 2024
38.9
Mar 2025
39.9
Mar 2026
45.2

Earnings per share(JPY per share)

Mar 2022
244.81
Mar 2023
-41.87
Mar 2024
122.81
Mar 2025
270.08
Mar 2026
606.28

Net assets per share(JPY per share)

Mar 2022
3,610.31
Mar 2023
3,593.49
Mar 2024
3,839.89
Mar 2025
4,044.52
Mar 2026
4,904.22

Dividend per share(JPY per share)

Mar 2022
80
Mar 2023
80
Mar 2024
65
Mar 2025
100
Mar 2026
150

Payout ratio(%)

Mar 2022
32.68
Mar 2023
-
Mar 2024
52.93
Mar 2025
37.03
Mar 2026
24.74

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.